Cyclodextrins as new formulation entities and therapeutic agents

Current Opinion in Anaesthesiology

Volumn 18, Issue 4, 2005, Pages 392-395

  Sikharam, Sreevalli ^a   Egan, Talmage D ^b   Kern, Steven E ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Bioavailability; Cyclodextrins; Formulation; Solubility

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; BUPIVACAINE; CYCLODEXTRIN; ETOMIDATE; GLIBENCLAMIDE; MIDAZOLAM; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEIC ACID; POLYMER; PROPOFOL; RECOMBINANT PROTEIN; ROCURONIUM; SUFENTANIL; SULFONYLUREA;

ANALGESIA; ANESTHESIA INDUCTION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; GASTROINTESTINAL SYMPTOM; GENE DELIVERY SYSTEM; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW;

EID: 23044458169     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000174962.28254.d7     Document Type: Review

References (22)

1. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo) 2004; 52:900-915. A good review of the physicochemical and biochemical characteristics of cyclodextrins, with an emphasis on applications in protein delivery.
2. Rajewski R, Stella V. Pharmaceutical applications of cyclodextrins. In vivo drug delivery. J Pharm Sci 1997; 85:1142-1168.
3. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 3:1023-1035. The most comprehensive review on cyclodextrins published during the review period.
4. Thompson DO. Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997; 14:1-104.
5. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003; 97:72-79.
6. Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2000; 7:249-271.
7. Doenicke A, Roizen MF, Nebauer AE, et al. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth Analg 1994; 79:933-939.
8. Dutta S, Ebling W. Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. J Pharm Pharmacol 1998; 50:37-42.
9. Bielen S, Lysko G, Gough W. The effect of cyclodextrin vehicle on the cardiovascular profile of propofol in rats. Anesth Analg 1996; 82:920-924.
10. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-1816.
11. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99:632-637.
12. Sparr HJ. Cyclodextrin. A new concept for antagonizing muscle relaxants [in German]. Anaesthesist 2002; 51:929-930.
13. Estebe JP, Ecoffey C, Dollo G, et al. Bupivacaine pharmacokinetics and motor blockade following epidural administration of the bupivacaine- sulphobutylether 7-beta-cyclodextrin complex in sheep. Eur J Anaesthesiol 2002; 19:308-310.
14. Meert TF, Mesens J, Verheyen P, Noorduin H. Hydroxypropyl-beta- cyclodextrin can modulate the activity of spinally administered sufentanil. Eur J Anaesthesiol 1992; 9:399-409.
15. Dollo G, Le Corre P, Freville JC, et al. Biopharmaceutics of local anesthetic-cyclodextrin complexes following loco-regional administration [in French]. Ann Pharm Fr 2000; 58:425-432.
16. Gudmundsdottir H, Sigurjonsdottir JF, Masson M, et al. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2001; 56:963-966.
17. Douhal A. Ultrafast guest dynamics in cyclodextrin nanocavities. Chem Rev 2004; 104:1955-1976. This article discusses the cyclodextrin physicochemistry factors that impact the release of the carried molecule.
18. Gonzalez H, Hwang SJ, Davis ME. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 1999; 10:1068-1074.
19. Pun SH, Bellocq NC, Liu A, et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem 2004; 15:831-840. This article discusses the development of a cyclodextrin-polymer carrier for gene therapy, and the benefits of these molecules for protein-based drug delivery.
20. Pun SH, Tack F, Bellocq NC, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 2004; 3:641-650. This article continues the previous citation discussing the pharmacological application of the carrier to cancer targeting.
21. Davis ME, Pun SH, Bellocq NC, et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr Med Chem 2004; 11:179-197. This article reviews the work of this research group in using cyclodextrin-based carriers for targeted drug delivery.
22. Redenti E, Szente L, Szejtli J. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci 2001; 90:979-986.